MOBILE-HEALTH NETWORK SOLUTI (MNDR)

KYG622641093 - Common Stock

0.398  +0.02 (+5.4%)

After market: 0.405 +0.01 (+1.76%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to MNDR. MNDR was compared to 107 industry peers in the Health Care Providers & Services industry. While MNDR seems to be doing ok healthwise, there are quite some concerns on its profitability. MNDR shows excellent growth, but is valued quite expensive already.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

MNDR had negative earnings in the past year.
MNDR had a negative operating cash flow in the past year.

1.2 Ratios

With a Return On Assets value of -214.63%, MNDR is not doing good in the industry: 97.14% of the companies in the same industry are doing better.
MNDR has a Return On Equity of -412.24%. This is amonst the worse of the industry: MNDR underperforms 85.71% of its industry peers.
Industry RankSector Rank
ROA -214.63%
ROE -412.24%
ROIC N/A
ROA(3y)-96.24%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

MNDR has a Gross Margin of 18.18%. This is in the lower half of the industry: MNDR underperforms 67.62% of its industry peers.
MNDR's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for MNDR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 18.18%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.09%
GM growth 5YN/A

More info and screens

6

2. Health

2.1 Basic Checks

MNDR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MNDR has been increased compared to 1 year ago.
MNDR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

MNDR has an Altman-Z score of -6.22. This is a bad value and indicates that MNDR is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -6.22, MNDR is doing worse than 89.52% of the companies in the same industry.
There is no outstanding debt for MNDR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.22
ROIC/WACCN/A
WACC9.24%

2.3 Liquidity

A Current Ratio of 2.31 indicates that MNDR has no problem at all paying its short term obligations.
The Current ratio of MNDR (2.31) is better than 79.05% of its industry peers.
MNDR has a Quick Ratio of 2.26. This indicates that MNDR is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of MNDR (2.26) is better than 79.05% of its industry peers.
Industry RankSector Rank
Current Ratio 2.31
Quick Ratio 2.26

More info and screens

7

3. Growth

3.1 Past

The earnings per share for MNDR have decreased strongly by -356.07% in the last year.
MNDR shows a strong growth in Revenue. In the last year, the Revenue has grown by 89.75%.
The Revenue has been growing by 75.52% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-356.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-493.67%
Revenue 1Y (TTM)89.75%
Revenue growth 3Y75.52%
Revenue growth 5YN/A
Sales Q2Q%77.38%

3.2 Future

MNDR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 46.76% yearly.
Based on estimates for the next years, MNDR will show a very strong growth in Revenue. The Revenue will grow by 78.77% on average per year.
EPS Next Y69.23%
EPS Next 2Y46.76%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year81.13%
Revenue Next 2Y78.77%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

MNDR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MNDR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as MNDR's earnings are expected to grow with 46.76% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y46.76%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

MNDR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MOBILE-HEALTH NETWORK SOLUTI

NASDAQ:MNDR (1/6/2025, 6:27:34 PM)

After market: 0.405 +0.01 (+1.76%)

0.398

+0.02 (+5.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)10-23 2024-10-23
Earnings (Next)N/A N/A
Inst Owners0.45%
Inst Owner Change0%
Ins Owners27.82%
Ins Owner ChangeN/A
Market Cap13.73M
Analysts82.86
Price Target8.16 (1950.25%)
Short Float %1.77%
Short Ratio0.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.67
P/FCF N/A
P/OCF N/A
P/B 3.32
P/tB 3.33
EV/EBITDA N/A
EPS(TTM)-0.6
EYN/A
EPS(NY)-0.04
Fwd EYN/A
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS0.6
BVpS0.12
TBVpS0.12
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -214.63%
ROE -412.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 18.18%
FCFM N/A
ROA(3y)-96.24%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.09%
GM growth 5YN/A
F-Score4
Asset Turnover2.59
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 90.03%
Cap/Sales 0.65%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.31
Quick Ratio 2.26
Altman-Z -6.22
F-Score4
WACC9.24%
ROIC/WACCN/A
Cap/Depr(3y)101.22%
Cap/Depr(5y)N/A
Cap/Sales(3y)1.18%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-356.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-493.67%
EPS Next Y69.23%
EPS Next 2Y46.76%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)89.75%
Revenue growth 3Y75.52%
Revenue growth 5YN/A
Sales Q2Q%77.38%
Revenue Next Year81.13%
Revenue Next 2Y78.77%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-272.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year69.85%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-168.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-184.86%
OCF growth 3YN/A
OCF growth 5YN/A